Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis by Wissing,  D. et al.
Proc. Natl. Acad. Sci. USA
Vol. 94, pp. 5073–5077, May 1997
Cell Biology
Involvement of caspase-dependent activation of cytosolic
phospholipase A2 in tumor necrosis factor-induced apoptosis
(apoptosisyarachidonic acidyCrmAyCPP32)
DORTE WISSING*, HELLE MOURITZEN*, MIKALA EGEBLAD*, GUY G. POIRIER†, AND MARJA JA¨A¨TTELA¨*‡
*Apoptosis Laboratory, Division for Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark; and †Health and
Environment Unit, Centre Hospitalier de l’Universite´ Laval Research Center, Quebec G1V 4G2, Canada
Communicated by Anthony Cerami, Cerami Consulting Corp., New York, NY, March 10, 1997 (received for review February 12, 1997)
ABSTRACT Tumor necrosis factor (TNF)-induced apo-
ptosis is mediated by caspases, which are cysteine proteases
related to interleukin 1b-converting enzyme. We report here
that TNF-induced activation of caspases results in the cleav-
age and activation of cytosolic phospholipase A2 (cPLA2) and
that activated cPLA2 contributes to apoptosis. Inhibition of
caspases by expression of a cowpox virus-derived inhibitor,
CrmA, or by a specific tetrapeptide inhibitor of CPP32y
caspase-3, acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-
CHO), inhibited TNF-induced activation of cPLA2 and apo-
ptosis. TNF-induced activation of cPLA2 was accompanied by
a cleavage of the 100-kDa cPLA2 to a 70-kDa proteolytic
fragment. This cleavage was inhibited by Ac-DEVD-CHO in a
similar manner as that of poly(ADP)ribose polymerase, a
known substrate of CPP32ycaspase-3. Interestingly, specific
inhibition of cPLA2 enzyme activity by arachidonyl trif lu-
oromethylketone (AACOCF3) partially inhibited TNF-
induced apoptosis without inhibition of caspase activity. Thus,
our results suggest a novel caspase-dependent activation
pathway for cPLA2 during apoptosis and identify cPLA2 as a
mediator of TNF-induced cell death acting downstream of
caspases.
Apoptosis is an active form of cell death controlled by the
expression of evolutionarily highly conserved genes, which
either activate or suppress the process of cell death (1). The
best studied activators of apoptosis include a growing family of
caspases, cysteine proteases related to interleukin 1b-
converting enzyme (ICEycaspase-1), which share sequence
homology with ced-3, a gene essential for apoptosis of nema-
todeCaenorhabditis elegans (2). Another family of activators of
apoptosis include proteins containing a ‘‘death domain’’ orig-
inally discovered in the intracellular parts of two receptors
capable of mediating apoptosis, type 1 tumor necrosis factor
receptor (TNF-R1) and Fas (3, 4). Recently, it was revealed
that binding of receptor death domains to each other and to
other intracellular proteins containing similar domains initiate
the apoptotic signaling: TNF-R1-associated death domain
protein (TRADD) binds to TNF-R1 (5), Fas-associated death
domain protein (FADDyMORT1) binds to either Fas or
TRADD (6, 7), and FLICEyMACHycaspase-8 binds to
FADD (8, 9), completing the death-inducing signaling com-
plex. Interestingly, FLICEyMACHycaspase-8 contains a
caspase-related cysteine protease domain, which possibly cou-
ples the receptor crosslinking and activation of apoptotic
protease cascade (8, 9). The importance of caspases in TNF-
and Fas-mediated apoptosis has been clearly demonstrated by
studies showing that (i) receptor activation leads to proteolytic
activation of at least three family members, FLICEyMACHy
caspase-8 (9), CPP32ycaspase-3 (10), and ICE-LAP3y
caspase-7 (11); (ii) inhibitors of caspases (cow pox virus
protein CrmA, baculovirus protein p35, and specific inhibitory
peptides) effectively block TNF- and Fas-mediated apoptosis
(12–16); and (iii) ectopic expression of caspases in several cells
results in apoptosis (2, 9, 11, 17, 18).
It is still largely unknown how TNF-induced activation of
caspases is linked to the activation of secondmessengers, which
eventually lead to the wide variety of TNF-induced effects
(19). Arachidonic acid generated as a result of cPLA2 activa-
tion has been implicated in a signal transduction pathway
resulting in cell death (20–25). Our new data showing that
TNF induces a cleavage of cPLA2 prompted us to study the role
of caspases in TNF-induced activation of cPLA2. Our results
show that inhibition of caspase activity inhibits both TNF-
induced cleavage and activation of cPLA2. Moreover, we show
that inhibition of cPLA2 activity partially inhibits TNF-induced
apoptosis. These results indicate that activation of cPLA2
requires caspases and that cPLA2 acts as a death mediator in
TNF-induced apoptosis.
MATERIALS AND METHODS
Cell Culture. MCF-7S1 cell line is a highly TNF-sensitive
subclone of MCF-7S breast carcinoma cells (26) and WEHI-S
cell line is a highly TNF sensitive subclone of WEHI 164
murine fibrosarcoma cells (27). Cells were cultured at 378C in
humidified air atmosphere with 5% CO2. RPMI 1640 medium
(GIBCO) supplemented with 10% heat-inactivated fetal calf
serum (FCS; GIBCO) and 2 mM each of glutamine, penicillin,
and streptomycin was used as a growth medium for all cell
lines. Medium used for the culture of transfected cell lines was
further supplemented with 0.2–0.4 mgyml of G418 (GIBCO).
All cell lines were tested and found negative for mycoplasma.
Treatments.Recombinant human TNF with specific activity
of 6 3 107 unitsyml was kindly provided by G. R. Adolf
(Ernst-Boehringer-Institute, Vienna). Acetyl-Tyr-Val-Ala-
Asp-aldehyde (Ac-YVAD-CHO; Bachem) and acetyl-Asp-
Glu-Val-Asp-aldehyde (Ac-DEVD-CHO; Neosystems, Stras-
bourg, France) were dissolved in water at 2 mM. Arachidonyl
trif luoromethylketone (AACOCF3) was from Biomol (Ply-
mouth Meeting, PA) and was dissolved in ethanol at 50 mM.
All experiments employing tetrapeptides and AACOCF3 were
performed in RPMImedium 1640 supplemented with 1% FCS
and cells were preincubated with them for 3 h before the
addition of TNF.
Electroporation. pcDNA3ycrmA and pcDNA3ycrmA-M
expression vectors encoding for cowpox virus-derived caspase
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inhibitor CrmA and its inactive mutant CrmA-M (point mu-
tation at amino acid 291, Thr to Arg) were kindly provided by
Vishva Dixit (University of Michigan Medical School, Ann
Arbor) (28). Twenty micrograms of circular plasmid DNA was
introduced into 107 cells in logarithmic growth phase by
electroporation as described previously (29). After 48 h at
378C, G418 (GIBCO) was added to a final concentration of 0.4
mgyml, and when the drug-resistant clones had reached con-
fluence they were individually collected and propagated.
Western Blot Analysis. Cells were lysed in urea sample
buffer (62.5 mM Tris, pH 6.8y6 M ureay10% glyceroly2%
SDSy0.003% bromophenol bluey5% 2-mercaptoethanol),
sonicated and incubated at 658C for 15 min before electro-
phoresis through 10% SDSyPAGE (30), and blotted to a
Hybond ECL filter (Amersham) using Miniblot graphite elec-
trophoresis unit (Millipore). Filters were incubated at 258C for
30 min in blocking buffer [5% low-fat milk powder in Tris-
buffered saline (TBS)], and 2 h in diluting buffer (0.5% low-fat
milk powder in TBS) containing the primary antibodies;
polyclonal rabbit antiserum specific for CrmA (28) (kindly
provided by Vishva Dixit) at 1:1000, mouse monoclonal anti-
body C2–10 recognizing poly(ADP)ribose polymerase
(PARP) (31) at 1:10000, and polyclonal rat antiserum specific
for cPLA2 at 1:200. After washing in TBS containing 0.08%
Tween-20, filters were incubated for 25 min at 258C in diluting
buffer containing 1:10000 dilution of peroxidase-conjugated
secondary antibody (Dako). After washing, chemilumines-
cence reaction was performed according to manufacturer’s
instructions using ECL Western blotting reagents (Amer-
sham); filters were exposed to ECL hyperfilm (Amersham) for
required time.
Production of Antiserum Recognizing cPLA2. To obtain an
antiserum recognizing human and mouse cPLA2, Wistar rats
were immunized subcutaneously with Freund’s complete ad-
juvant containing 20–40 nmol of a Diphtheria toxoid-coupled
synthetic peptide CPDPYVELFISTTPDSRK (Chiron Mimo-
topes), sequence except for the N-terminal cysteine corre-
sponding to amino acids 43–58 in both mouse and human
FIG. 1. Expression of CrmA and mutant CrmA (CrmA-M) in
stably transfected single cell clones of WEHI-S (a) and MCF-7S1 cells
(b). Cells were transfected with empty pcDNA3 vector (V) or with the
same vector containing cDNAs encoding for CrmA (CrmA) or for
inactive mutant of CrmA (CrmA-M) (28) by electroporation as
described (29). Cell lysates from approximately 23 105 G418-resistant
single cell clones were analyzed by Western blot analysis using
polyclonal antiserum against CrmA (28). The migration of molecular
weight markers from NOVEX (San Diego) is indicated on the left.
FIG. 2. CrmA inhibits TNF-mediated cy-
totoxicity (a and b) and release of arachidonic
acid (c and d) in WEHI-S (a and c) and
MCF-7S1 (b and d) cells. (a and b) Ten
thousand cells per well were plated in 96-well
microtiter plates with the indicated concen-
trations of TNF. The percentage of surviving
cells were analyzed by the MTT assay (29)
after 6 h (a) or 48 h (b) incubation. (c and d)
Cells (2 3 105) labeled with [3H]arachidonic
acid were plated in 24-well plates. After 4 h
(c) or 20 h (d) incubation with indicated
concentrations of TNF, radioactivity released
to the supernatant was analyzed. The release
of radiolabeled arachidonic acid is reported
relative to spontaneous release from cells
without TNF (1.0). Cell clones are as in Fig.
1. The values represent means of a triplicate
experiment. Experiments were repeated
three or four times with similar results.
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cPLA2 (32). Immunization was repeated after 2 and 5 weeks
using Freund’s incomplete adjuvant. Plasma was collected 1
week after the last immunization.
Functional Assays. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) tetrazolium assay was
used to measure the viability and 51Cr-release assay was used
to measure the death of cells as described previously (26, 33).
Activation of cPLA2 was analyzed as described previously (23)
by an assay based on labeling of cells with [3H]arachidonic acid
[5,6,8,9,11,12,14,15-3H(N)] (80 Ciymmol, 0.1 mCiyml; 1 Ci 5
37 GBq; NEN) and measurement of released radioactivity
from the supernatant after treatment.
RESULTS
Expression of CrmA Renders Cells Resistant to TNF-
Mediated Cytotoxicity. Expression plasmids encoding for a
cowpox virus-derived inhibitor of caspases, CrmA, or its
inactive mutant, CrmA-M, were introduced into WEHI-S
mouse fibrosarcoma and MCF-7S1 human breast carcinoma
cells by electroporation. We have previously demonstrated
that TNF induces morphological changes characteristic of
apoptosis in these cell lines (29). G418-resistant transformants
were analyzed by Western blot analysis for the expression of
CrmA and CrmA-M and two clones with highest expression
levels from each transfection (WEHI-CrmA-4 and -8, WEHI-
CrmA-M1 and -M4, MCF-CrmA-6 and -7, and MCF-
CrmA-M6 and -M8) and randomly selected vector-transfected
control clones (WEHI-V1 andMCF-V1) were used for further
studies (Fig. 1).
Parental cell lines and obtained transformants were treated
with various concentrations of TNF, and the viability of cells
was analyzed by MTT assay. Expression of CrmA, but not that
of CrmA-M, conferred clear protection from TNF-induced
cytotoxicity confirming that the activation of caspases is
involved in TNF-mediated killing of the cells used in this study
(Fig. 2 a and b).
TNF-Induced Activation of cPLA2 Requires Caspase Activ-
ity. In various sensitive target cells, including WEHI-S and
MCF-7S1 cells, the activation of cPLA2 by TNF has been
shown to lead to the enzymatic release of arachidonic acid
from membrane phospholipids (20–25). To test whether acti-
vation of cPLA2 is dependent on the activation of caspases,
TNF-induced activation of cPLA2 in cells expressing CrmA or
CrmA-M were analyzed by measuring the release of radioac-
tivity from cells labeled with [3H]arachidonic acid. A 4-h
exposure of WEHI-S cells to TNF at concentrations ranging
from 0.1–10 ngyml induced a dose-dependent release of
radioactivity, the maximum release being approximately 5-fold
higher than that from cells incubated in media alone (Fig. 2c).
The release of radioactivity from transfection control cells
(WEHI-V1) in response to TNF did not differ significantly
from that in parental cells, indicating that transfection proce-
dure had not affected the activation of arachidonic acid
metabolism. Interestingly, TNF-induced activation of cPLA2 in
clones expressing CrmA (WEHI-CrmA-4 and -8) was inhibited
in a similar manner as TNF-mediated cytotoxicity (Fig. 2 a and
c). Similar results were obtained with MCF-7S1 transformants
(Fig. 2 b and d). CrmA-M was unable to inhibit TNF-induced
activation of cPLA2, indicating that CrmA-mediated inhibition
of cPLA2 was due to inhibition of caspases and not to other
putative activities of CrmA. This was further confirmed by
results showing that a specific tetrapeptide inhibitor of CPP32y
caspase-3, Ac-DEVD-CHO (34), at concentrations that inhib-
ited TNF-induced apoptosis also inhibited arachidonic acid
release (Fig. 3). An ICEycaspase-1-specific tetrapeptide in-
hibitor, Ac-YVAD-CHO (34), had a similar effect, but ap-
proximately 10 times higher concentrations were needed for
the inhibition (data not shown). Inhibition of the release of
arachidonic acid was not due to the better survival of cells as
the assay was performed at a time point when cell membranes
were not yet damaged as analyzed by trypan blue exclusion and
chromium release assays (data not shown). Moreover, killing
the cells by freezing and thawing did not result in the release
of arachidonic acid.
TNF Induces a Caspase-Dependent Cleavage of cPLA2.
Inspection of the published protein sequence of human cPLA2
(35) revealed a sequence DELD, identical to that recognized
by CPP32ycaspase-3 in D4-GDI protein (36) and very similar
to the CPP32ycaspase-3 recognition sequence DEVD in
PARP (28). The DELD sequence is conserved in mouse, rat,
and chicken cPLA2 (32). We therefore studied the possible
cleavage of cPLA2 following TNF-treatment by Western blot
analysis using a rat antiserum raised against a Diphtheria
toxoid-coupled synthetic peptide corresponding to amino acids
43–58 in both mouse and human cPLA2. The obtained anti-
serum recognized a single specific band of the expected size,
approximately 100 kDa (35), in Western blot analysis of
proteins from non-treated WEHI-S cells (Fig. 4a and 5b).
TNF-treatment of WEHI-S cells resulted in a dose- and
time-dependent cleavage of the 100-kDa cPLA2 to an approx-
imately 70-kDa proteolytic fragment recognized by the anti-
serum. The putative CPP32ycaspase-3 cleavage site is at the
amino acid 522 of 749 amino acids and as the antibody was
FIG. 3. Inhibition of CPP32ycaspase-3 inhibits TNF-induced cy-
totoxicity and activation of cPLA2 in WEHI-S (a) and MCF-7S1 (b)
cells. Cytotoxicity induced by TNF was analyzed by 6 h (a) or 24 h (b)
chromium release assay and the cPLA2 activity was analyzed by
measuring the release of arachidonic acid following 4 h (a) or 18 h (b)
incubation with TNF. Cells were incubated for 3 h with indicated
concentrations of Ac-DEVD-CHO before the addition of 10 ngyml of
TNF. The values represent means of a triplicate experiment. Exper-
iments were repeated twice with similar results.
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raised against a peptide in the amino terminus of the protein,
the 70-kDa fragment seen could present the first 522 amino
acids. The appearance of the 70-kDa fragment occurred at
similar doses of TNF (Fig. 5 b and c) and with similar kinetics
(Fig. 4) as that of the 85-kDa apoptotic fragment of PARP.
Moreover, TNF-induced cleavage of cPLA2 was inhibited by
Ac-DEVD-CHO in a similar manner as that of PARP (Fig. 4).
The expression level of cPLA2 in MCF-7S1 cells was under
the detection limit of the assay. To test whether cleavage of
cPLA2 also occurs in human cells, we transfected MCF-7S1
cells with an expression construct encoding for human cPLA2.
In the resulting MCF-cPLA2 cells, a 100-kDa cPLA2 band was
clearly detectable and it was cleaved to the 70-kDa fragment
following 18 h TNF treatment (data not shown).
Inhibition of cPLA2 Activity Partially Inhibits TNF-
Mediated Cytotoxicity. We next studied whether a specific
inhibition of TNF-induced activation of cPLA2 inhibits TNF-
mediated apoptosis. Remarkably, inhibition of TNF-induced
release of arachidonic acid by a specific cPLA2 inhibitor, a
trif luoromethylketone analog of arachidonic acid (AA-
COCF3) (37), was accompanied by a dose-dependent inhibi-
tion of TNF-induced cytotoxicity indicating that activation of
cPLA2 contributes to TNF-mediated cytotoxicity (Fig. 5a).
Inhibition of TNF-induced cell death by AACOCF3 had no
effect on the activity of caspases as analyzed by the appearance
of the apoptotic fragments of cPLA2 and PARP (Fig. 5 b and
c).
DISCUSSION
The results presented above demonstrate a novel activation
pathway for cPLA2. The classical cPLA2 activation pathway
involves an agonist-induced phosphorylation of cPLA2 at
Ser-505 by mitogen-activated protein kinase and calcium-
dependent translocation of cPLA2 from cytosol to membranes
where the substrate is localized (35, 38, 39). TNF-mediated
activation of cPLA2 in WEHI-S cells did not result in its
phosphorylation as judged by the lack of phosphorylation-
associated electrophoretic mobility-shift of cPLA2 protein
(Figs. 4a and 5b; ref. 39). The ability of caspase inhibitors,
CrmA (Fig. 2) and Ac-DEVD-CHO (Fig. 3), to inhibit TNF-
induced arachidonic acid release in tumor cells indicates that
cPLA2 is activated by a pathway involving caspases. This is
consistent with earlier results showing that inhibition of TNF-
mediated apoptosis by various protective proteins acting up-
stream from caspases, heat shock protein 70 (23), A20 (29),
Bcl-2 and Bcl-x (26), and adenovirus protein E3 14.7-kDa (40)
is always accompanied by inhibition of TNF-induced activation
of cPLA2.
Interestingly, TNF-treatment resulted in the cleavage of the
100-kDa cPLA2 into an approximately 70-kDa fragment. As
cPLA2 contains a CPP32ycaspase-3 recognition sequence and
as Ac-DEVD-CHO inhibited cPLA2 cleavage in a similar
manner as it inhibited the cleavage of a CPP32ycaspase-3
substrate, PARP, cPLA2 is likely to be cleaved by CPP32y
caspase-3 or a closely related protease. Whether TNF-induced
activation of cPLA2 in apoptosis is a result of its proteolysis and
one of its proteolytic fragments is functioning as an active
enzyme remains to be studied. Alternatively, a putative cPLA2-
inhibitor (41) could be inactivated by caspases or cPLA2 could
be activated by other caspase-activated enzymes, like protein
kinase C d (42, 43), or by other yet unknown substrates.
FIG. 4. Western blot demonstrating TNF-induced and Ac-DEVD-
CHO-inhibited cleavage of cPLA2 (a) and PARP (b). WEHI-S cells
were incubated for 3 h with (1) or without (2) 100 mM of Ac-DEVD-
CHO and were then treated with 50 ngyml of TNF for indicated times.
Cell lysates from approximately 2 3 105 cells were prepared and
analyzed by Western blotting as described (31) using 1:200 dilution of
polyclonal rat antiserum against cPLA2 (a) or 1:10000 dilution of
monoclonal mouse anti-PARP antibody (31) (b) and ECL reagents
from Amersham. The migration of molecular weight markers from
NOVEX are indicated on the left.
FIG. 5. A specific cPLA2 inhibitor, AACOCF3, inhibits TNF-
induced cytotoxicity and release of arachidonic acid (a) without
affecting ICE-like protease activity (b and c). (a) WEHI-S cells were
preincubated for 3 h with indicated concentrations of AACOCF3.
Cytotoxicity percentage was determined by chromium release assay
and the cPLA2 activity by measuring the release of arachidonic acid
after 6 h and 4 h incubation with 10 ngyml of TNF, respectively. (b and
c) Cells were incubated for 3 h with (1) or without (2) 10 mM
AACOCF3 and then treated with indicated concentrations of TNF for
6 h. Western blot analysis was as described in the legend for Fig. 4.
5076 Cell Biology: Wissing et al. Proc. Natl. Acad. Sci. USA 94 (1997)
Activation of cPLA2 has been suggested to be essential for
TNF-mediated cytotoxicity in L929 cells as TNF-resistant
L929 mutants that had lost the expression of cPLA2 could be
rendered TNF sensitive by exogenous expression of cPLA2
(24). Moreover, inhibition of cPLA2 expression by antisense
oliconucleotides has been shown to render melanoma cells
resistant to TNF-mediated cytotoxicity (25). Present data
showing that a specific cPLA2 inhibitor, AACOCF3, inhibits
TNF-mediated cell death, further supports the hypothesis that
cPLA2 is an essential part of TNF-induced death pathway. The
mechanism by which cPLA2 mediates apoptosis is still unclear.
As it is activated by caspases it must act in the final execution
step of apoptosis. cPLA2-mediated cleavage of arachidonic
acid from membranes may disrupt the integrity of various
cellular membranes. Alternatively, the released arachidonic
acid may act as a second messenger and activate other apo-
ptosis associated enzymes like sphingomyelinase (44).
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